In a boost to vaccine development, structure of SARS-CoV-2 key protein mapped

This will allow better understanding of how the virus binds to the human cells.

Updated - February 22, 2020 07:18 pm IST

Published - February 22, 2020 06:14 pm IST

Researchers at the University of Texas at Austin and the National Institutes of Health, U.S., have produced a 3D atomic scale map of the protein of the novel coronavirus (SARS-CoV-2) that binds to and infects human cells.

Researchers at the University of Texas at Austin and the National Institutes of Health, U.S., have produced a 3D atomic scale map of the protein of the novel coronavirus (SARS-CoV-2) that binds to and infects human cells.

Researchers at the University of Texas at Austin and the National Institutes of Health, U.S., have produced a 3D atomic scale map of the protein of the novel coronavirus (SARS-CoV-2) that binds to and infects human cells.

Mapping the 3D structure of the protein — spike (S) glycoprotein — will allow better understanding of how the virus binds to the human cells. Knowing the structure of the spike protein will, in turn, allow scientists to develop vaccines and antivirals against the virus and even better diagnostics.

Shape of the virus

Like other coronaviruses, SARS-CoV-2 virus particles are spherical and have mushroom-shaped proteins called spikes protruding from their surface, giving the particles a crown-like appearance. The spike binds and fuses to human cells, allowing the virus to gain entry.

The spike protein of the novel coronovirus shares 98% sequence identity with the spike protein of the bat coronavirus, the researchers say. The results were published in the journal Science.

Similar yet different

The researchers also found that like in the case of the SARS coronavirus, the spike protein of the novel coronavirus (SARS-CoV-2) that causes COVID-19 disease binds to the cellular receptor called angiotensin-converting enzyme 2 (ACE2), which serves as the entry point into human cells. But unlike in the case of SARS, the spike protein of the novel coronavirus binds to the cell receptor with much higher affinity — 10- to 20-fold higher.

Greater binding affinity

The much greater binding affinity to the cell receptor explains the apparent high human-to-human transmissibility of the virus compared with the SARS coronavirus.

“The high affinity of the 2019-nCoV S for human ACE2 may contribute to the apparent ease with which the 2019-nCoV can spread from human-to-human,” the researchers write. “Additional studies are needed to investigate this possibility.”

Since both the SARS coronavirus and the 2019 novel coronavirus share structural similarity and bind to the same receptor, the researchers tested three monoclonal antibodies specific to SARS virus for their ability to bind to the novel coronavirus. But none of the three antibodies tested were found to be effective in inhibiting the novel coronavirus from binding to the human receptor ACE2 and prevent or treat the disease.

New antivirals

However, the 3D map of the S protein will help researchers design new antivirals to stop the virus from binding and infecting human cells.

“Knowing the atomic-level structure of the 2019-nCoV spike will allow for additional protein engineering efforts that could improve antigenicity and protein expression for vaccine development,” the researchers write.

The researchers were able to determine the structure of the spike protein as the Chinese researchers shared the whole genome sequence data in the global database.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.